Literature DB >> 12118775

Cardiomyocyte transplantation does not reverse cardiac remodeling in rats with chronic myocardial infarction.

Yutaka Sakakibara1, Keiichi Tambara, Fanglin Lu, Takeshi Nishina, Noritoshi Nagaya, Kazunobu Nishimura, Masashi Komeda.   

Abstract

BACKGROUND: Several reports have documented the potential benefits of cell transplantation as an alternative to cardiac transplantation. This study was designed to investigate whether cardiomyocyte transplantation is effective in rats with chronic myocardial infarction.
METHODS: Syngeneic Lewis rats were used in this study. Chronic myocardial infarction was induced in rats by ligating the left anterior descending artery. Four weeks later, after left ventricular (LV) dysfunction with akinetic regions was confirmed by echocardiography, the rats were randomized into two groups: a group that received fetal cardiomyocyte transplantation (TX group; n = 11); and a group that received an intramyocardial injection of culture medium only (control group; n = 12).
RESULTS: Four weeks after treatment, the TX group had smaller end-systolic dimension (LVDs) (7.5 +/- 0.9 vs 8.9 +/- 0.8 mm, p < 0.01) and better fractional shortening (FS) (26.2 +/- 5.9 vs 17.7% +/- 5.1%, p < 0.01) than the control group. However, there were no differences in LV end-diastolic dimension, LVDs, and FS between baseline and post-treatment values in the TX group. In addition, plasma levels of atrial natriuretic peptide were not significantly different between the two groups 4 weeks after treatment. In microscopic examination, small amounts of transplanted cardiomyocytes were found only in the periinfarct area, not in the center of scar area, and a thicker ventricular wall in the infarct area was detected in the TX group.
CONCLUSIONS: Fetal cardiomyocyte transplantation prevented, but did not reverse, cardiac remodeling that was accompanied with heart failure in myocardial infarction rats. Further investigation is warranted for optimal clinical application to the failing heart.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12118775     DOI: 10.1016/s0003-4975(02)03601-9

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  5 in total

1.  Human embryonic stem cell-derived cardiomyocytes engraft but do not alter cardiac remodeling after chronic infarction in rats.

Authors:  S Fernandes; A V Naumova; W Z Zhu; M A Laflamme; J Gold; C E Murry
Journal:  J Mol Cell Cardiol       Date:  2010-09-18       Impact factor: 5.000

2.  Assessment of the effect of cardiomyocyte transplantation on left ventricular remodeling and function in post-infarction Wister rats by using high-frequency ultrasound.

Authors:  Jing Zhang; Mingxing Xie; Xinfang Wang
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2007-12

Review 3.  Diabetic heart dysfunction: is cell transplantation a potential therapy?

Authors:  Joel Price; Subodh Verma; Ren-Ke Li
Journal:  Heart Fail Rev       Date:  2003-07       Impact factor: 4.214

Review 4.  Myoblast-based cell transplantation.

Authors:  Philippe Menasché
Journal:  Heart Fail Rev       Date:  2003-07       Impact factor: 4.214

5.  Effect of a simple versus a complex matrix on the polarity of cardiomyocytes in culture.

Authors:  Rachel A Davis; W Barry van Winkle; L Maximilian Buja; Brian J Poindexter; Roger J Bick
Journal:  J Burns Wounds       Date:  2006-03-30
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.